E.I. YUNUSOVA¹, O.V. DANILOVA², R.D. GIZATULLINA²

¹Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

²Biomed Clinical-diagnostic center Ltd., Kazan

 Contact: details:

Yunusova E.I. — PhD (medicine), Associate Professor of the Department of Dermatovenerology and Cosmetology

Address: 36 Butlerov St., Kazan, Russian Federation, 420011, tel.: +7-919-635-28-61, e-mail: elenaiu@mail.ru

 In the recent decades, the viral urogenital pathology increases, with papilloma viral infection dominating in the structure of such diseases. The occurrence and development of a papilloma-associated pathology, the severity of the disease and a probable outcome directly depend on the immune status and ability of the body to react to the pathogen. The papilloma infection may become a serious problem during pregnancy, which determines the need to examine and treat women when planning pregnancy. Regardless of the method of destruction of anogenital warts, the probability of the pathology relapse remains high, sometimes up to 60%. The use of Imunofan in the complex treatment of women with relapsing anogenital papilloma viral pathology showed its high efficiency, namely, a large percentage of the virus elimination, low level of relapses, activation of anti-viral immunity and good acceptability of the treatment.

Key words: papilloma viral infection, papilloma-associated pathology, immunity.

REFERENCES

1. Blatova O.L., Kontorshchikova K.N., Andosova L.D., Mikhaleva O.V., Kudel’kina S.Yu. Analysis of the frequency of detection of oncogenic types of human papillomavirus in women with gynecological pathology. Vestnik dermatologii i venerologii, 2011, no. 1, pp. 66–69 (in Russ.).
2. Ibishev Kh.S., Kogan M.I. Papillomavirusnaya infektsiya u muzhchin [Papillomavirus infection in men]. Rostov on Don: GBOU VPO «RostGMU», 2012. 52 p.
3. Yunusova E.I., Danilova O.V., Gizatullina R.D. Panavir in the treatment of patients with recurrent papillomavirus infection of the urogenital tract. Dnevnik kazanskoy meditsinskoy shkoly, 2016, no. 11 (XII), pp. 118–121 (in Russ.).
4. Rogovskaya S.I., Bebneva T.N. Regression of genital warts and mild cervical intraepithelial neoplasia on the background of immunotherapy (clinical observation). RMZh. Mat’ i ditya, 2020, no. 2, pp. 100–104 (in Russ.).
5. Yunusova E.I., Danilova O.V., Yusupova L.A., Mavlyutova G.I., Garaeva Z.Sh. Papillomavirus infection and pregnancy. Peculiarities of diagnostics and tactics of management. Lechashchiy vrach, 2018, no. 5, pp. 56–59 (in Russ.).
6. Rogovskaya S.I. Papillomavirusnaya infektsiya u zhenshchin i patologiya sheyki matki [Papillomavirus infection in women and pathology of the cervix]. Moscow: GEOTAR-Media, 2005. Pp. 15–17.
7. Yunusova E.I., Yusupova L.A., Mavlyutova G.I., Garaeva Z.Sh. Flat warts: features and possibilities of therapy. Lechashchiy vrach, 2016, no. 5, pp. 52–55 (in Russ.).
8. Aguilar-Martinez E., Morrisroe C., Sharrocks A.D. The ubiquitin ligase UBE3A dampens ERK pathway signalling in HPV E6 transformed HeLa cells. PLoS One, 2015, Mar, vol. 10 (3), p. 11.
9. Holloway A., Simmonds M., Azad A., Fox J.L., Storey A. Resistance to UV-induced apoptosis by β-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. Int J Cancer, 2015, vol. 136 (12), pp. 2831–2843.
10. Jing K., Shin S., Jeong S., Kim S., Song K.S., Park J.H., Heo J.Y., Seo K.S., Park S.K., Kweon G.R., Wu T., Park J.I., Lim K. Docosahexaenoic acid induces the degradation of HPV E6/E7 oncoproteins by activating the ubiquitin-proteasome system. Cell Death Dis, 2014, Nov, vol. 5, p. 1524.
11. Kiselev V.I. Virusy papillomy cheloveka v razvitii raka sheyki matki [Human papillomaviruses in the development of cervical cancer]. Moscow: Kompaniya «Dimitreyd Grafik Grupp», 2004. 180 p.
12. Dmitriev G.A., Bitkina O.A. Papillomavirusnaya infektsiya [Papillomavirus infection]. Moscow: Meditsinskaya kniga, 2006. 76 p.
13. Danilova O.V., Yunusova E.I. Taktika vedeniya papillomavirusnykh porazheniy genitaliy: uchebnoe posobie dlya vrachey [Tactics of managing papillomavirus lesions of the genitals: a textbook for doctors]. Kazan, 2012. 30 p.
14. Cobos C., Figueroe J.A., Mrandda L. Et al. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy a review. Int Rev Immunol, 2014, vol. 33 (5), pp. 383–401.
15. Rakhmatullina M.R., Nechaeva I.A., Shalva Mardi. Experience in destructive therapy of anogenital warts. Vestnik dermatologii i venerologii, 2016, no. 5, pp. 96–101 (in Russ.).
16. Tavares M.C., de Lima Junior S.F., Coelho A.V. et al. Ann Hum Biol, 2015, Jun, vol. 16, pp. 1–8.
17. Prabhavathy D., Subramanian C.K., Karunagaran D. Re-expression of HPV16 E2 in Si Ha (human cervical cancer) cell potentiates NF-kB activation induced by TNF-α concurrently increasing senescence and survival. Bio sci Rep, 2015, Feb, vol. 35 (1).
18. Sukhikh G.T., Prilepskaya V.N, Rogovskaya S.I. et al. The use of interferon preparations in the treatment of low-grade squamous intraepithelial lesions of the cervix. Effektivnaya farmakoterapiya v akusherstve i ginekologii, 2009, no. 4, pp. 36–41 (in Russ.).
19. Krasnopol’skiy V.I., Zarochentseva N.V., Mikaelyan A.V., Keshch’yan L.V., Lazarev I.N. The role of papillomavirus infection in the pathology of pregnancy and outcome for the newborn (modern concepts). Rossiyskiy vestnik akushera-ginekologa, 2016, no. 2, pp. 30–36 (in Russ.).
20. Dolgushina N.V. Immunological aspects of the development of placental insufficiency and miscarriage in patients with chronic viral infections. Akusherstvo i ginekologiya, 2008, no. 4, pp. 16-19 (in Russ.).
21. Wicherek L., Basta P., Sikora J. et al. RCAS1 decidual immunoreactivity in servere pre-eclampsia: Immune cell pre-cence and activity. Amer. J. Period. Immunol, 2007, vol. 68 (4), pp. 358–366.
22. Mitra A., Kindinger L., Kalliala I. et al. Obstetric complications after treatment of cervical intraepithelial neoplasia. Br. J. Hosp. Med. (Lond), 2016, vol. 77 (8), pp. C124–C127. DOI: 10.12968/hmed.2016.77.8.C124
23. Bebneva T.N. Modern ideas about the impact of human papillomavirus infection on the course of pregnancy. Vozmozhnosti immunokorrektsii. RMZh, 2018, pp. 2–5 (in Russ.).
24. Vorobtsova I.N., Tapil’skaya N.I., Gaydukov S.N. The results of the examination of newborns born to mothers with various forms of human papillomavirus infection. Pediatr, 2011, vol. II, no. 4, pp. 72–75 (in Russ.).
25. Chistyakov M.A. Patomorfologiya papillomavirusnoy infektsii v sisteme «mat’-platsenta-plod»: avtoref. dis… kan. med. nauk [Pathomorphology of human papillomavirus infection in the «mother-placenta-fetus» system. Synopsis of dis. PhD med. sciences]. Moscow, 2008. 25 p.
26. Sedlacek T. V., Lindheim S. et al. Mechanism for HPV transmission at birth. Am J Obstet Gynecol, 1989, vol. 161, pp. 55–59.
27. Watts D. H., Koutsky L. A. et al. Low-risk perinatal transmission of HPV: results from a prospective cohort study. Am J Obstet Gynecol, 1989, vol. 178, pp. 365–373.
28. Korolenkova L.I., Ermilova V.D. Involvement of endocervical crypts as a negative predictor of intraepithelial neoplasia and microinvasive cervical cancer. Vestnik RONTs im. N.N. Blokhina RAMN, 2011, vol. 22, no. 3(85), pp. 70–76 (in Russ.).
29. Lebedeva M.I. Papillomavirus infection: new possibilities of therapy. Poliklinika, 2009, no. 2, pp. 92–93 (in Russ.).